Catalyst Dossier · compiled by CeliA 🧫

Aldeyra Therapeutics, Inc. (ALDX)

Pharmaceutical Preparations · market cap $118M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Reproxalap Ophthalmic Solution (0.5%)	Phase 3	Allergic Conjunctivitis
ADX-102 Ophthalmic Drops (0.5%)	Phase 2	Conjunctivitis, Allergic
ADX-2191	Phase 2	Retinitis Pigmentosa
ADX-629	Phase 2	Ethanol Intoxication
ADX-629 (Open-label)	Phase 2	Atopic Dermatitis
Xiidra® (5% lifitegrast ophthalmic solution)	Phase 2	Dry Eye
NS2 Ophthalmic Drops (0.5%)	Phase 2	Allergic Conjunctivitis
ADX-102 1% Topical Dermal Cream (reproxalap)	Phase 3	Sjogren-Larsson Syndrome
Active topical NS2 1% dermatologic cream	Phase 2	Sjögren-Larsson Syndrome
NS2	Phase 2	Non-infectious Anterior Uveitis
ADX-2191 (intravitreal methotrexate 0.8%)	Phase 3	Proliferative Vitreoretinopathy
Reproxalap Ophthalmic Solution (0.1%)	Phase 2	Dry Eye Syndrome
Reproxalap Ophthalmic Solution (0.25%) QID	Phase 3	Dry Eye
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID	Phase 3	Dry Eye
ADX-102 Ophthalmic Solution (0.5%)	Phase 3	Dry Eye Syndromes
Reproxalap Ophthalmic Solution (0.25%)	Phase 3	Dry Eye Syndromes

Price & technical context

3-month

+43.8%

6-month

-53.0%

12-month

-36.6%

52-wk range

$1.24–$5.89

vs 50-day MA

+39.9%

vs 200-day MA

-36.5%

Realized vol

147.5%

Max drawdown

-82.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALDX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 16 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.